Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil for reperfusion after ovarian detorsion
IRCT20191104045328N36Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of sildenafil in ovarian torsion (OT) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Ovarian artery pulsatility index, Ovarian artery resistance index and 2 more. Started May 2025; status: completed.
02
Drugs
sildenafil
03
Conditions
ovarian torsion (OT)
Beyond the preview
Go deeper on IRCT20191104045328N36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191104045328N36.